Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk’s blockbuster drug Ozempic, through its platform.
The generic semaglutide is made by Apotex Inc, the largest Canada-based global health company, Hims said, marking the telehealth platform’s first international generic GLP-1 offering.
The expiry of Novo’s patent for semaglutide has opened the door for several drugmakers looking to enter the Canadian market with generic versions, which are essentially copies of branded drugs.
Health Canada had approved Apotex’s drug earlier this month. Last week, the company launched its generic drug, Apo-Semaglutide Injection, indicated for once-weekly treatment of adults with type 2 diabetes.
Indian drugmaker Dr Reddy’s also received the green light last month, and has launched its generic version in the country.
The price of Ozempic in Canada ranges between $200 and $400 per month, depending on dosage, region and insurance.
“When more affordable options enter the GLP-1 space, it becomes more dynamic, and prices fall across the board. That benefits patients everywhere, regardless of where they seek care,” said Sandy Van, chief medical officer at Hims & Hers Canada.
Canadians will be able to receive personalized plans starting at $149 per month, the company said.
The telehealth firm said it is open to partnering with other manufacturers in Canada, but did not share further details.
(Reporting by Sriparna Roy in Bengaluru; Editing by Sahal Muhammed)
